HALOZYME THERAPEUTICS, INC. (HALO) 2025年第一季度财报(10-Q)「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-Q(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1934For the quarterly period ended March 31,2025ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1

2、934For the transition period from to Commission File Number 001-32335_HALOZYME THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)_Delaware 88-0488686(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)12390 El Camino Real 92130San Die

3、go(Zip Code)California(Address of principal executive offices)(858)794-8889(Registrants telephone number,including area code)Not Applicable(Former name,former address and former fiscal year,if changed since last report)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrad

4、ing Symbol(s)Name of each exchange on which registeredCommon Stock,$0.001 par valueHALOThe Nasdaq Stock Market LLCIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12 months(or f

5、or such shorter period that the registrant was required to file such reports),and(2)has been subject tosuch filing requirements for the past 90 days.Yes x No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Ru

6、le405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was required tosubmit such files).Yes x No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller r